Literature DB >> 25128453

Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug naïve, first episode schizophrenia.

Xueqin Song1, Xiaoduo Fan2, Xue Li3, David Kennedy2, Lijuan Pang3, Meina Quan2, Xumei Chen3, Jinsong Gao3, Wei Zhang3, Jianjiang Zhang3, Luxian Lv4.   

Abstract

OBJECTIVE: The present study was to examine serum levels of brain-derived neurotrophic factor (BDNF), folate, homocysteine (Hcy), and their relationships with hippocampal volume and psychopathology in drug naïve, first episode schizophrenia.
METHOD: Drug naïve, first episode schizophrenia patients and healthy controls were enrolled in the study. Serum levels of BDNF, folate and Hcy were measured using enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence immunoassay (ECLIA), and enzymatic cycling method respectively. Hippocampus was parcellated and bilateral hippocampal volumes were measured using FreeSurfer.
RESULTS: Forty-six patients with drug naïve, first episode schizophrenia (SZ group) and 30 healthy controls (control group) were enrolled. The SZ group had significantly lower serum levels of BDNF and folate, and significantly higher serum levels of Hcy compared with the control group (p=0.013, p<0.001, p=0.003 respectively). There were no significant differences in hippocampal volumes between the two groups (ps>0.2). Within the SZ group, there were significant positive relationships between serum levels of BDNF and both left and right hippocampal volumes (r=0.327, p=0.026; r=0.338, p=0.022 respectively). In contrast, such relationships did not exist in the control group. Within the SZ group, there were significant negative relationships between serum levels of folate and PANSS-total scores and PANSS-negative symptom scores (r=0.319, p=0.031; r=0.321, p=0.030 respectively); and there was a positive relationship between serum levels of Hcy and PANSS-total scores (r=0.312, p=0.035). Controlling for potential confounding variables resulted in similar findings.
CONCLUSIONS: Drug naïve, first episode schizophrenia presents decreased serum levels of BDNF, folate and increased serum levels of Hcy, which may play an important role in the neurodevelopmental process and clinical manifestation of schizophrenia.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  BDNF; Folate; Hippocampus; Homocysteine; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25128453     DOI: 10.1016/j.schres.2014.07.033

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  17 in total

1.  Maternal Folic Acid Supplementation During Pregnancy Improves Neurobehavioral Development in Rat Offspring.

Authors:  Xinyan Wang; Wen Li; Shou Li; Jing Yan; John X Wilson; Guowei Huang
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 2.  Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Meenakshi Dauwan; Marieke J H Begemann; Sophie M Heringa; Iris E Sommer
Journal:  Schizophr Bull       Date:  2015-11-07       Impact factor: 9.306

Review 3.  A Meta-Analysis of Brain-Derived Neurotrophic Factor Effects on Brain Volume in Schizophrenia: Genotype and Serum Levels.

Authors:  Anthony O Ahmed; Samantha Kramer; Naama Hofman; John Flynn; Marie Hansen; Victoria Martin; Anilkumar Pillai; Peter F Buckley
Journal:  Neuropsychobiology       Date:  2021-03-11       Impact factor: 2.328

4.  Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis.

Authors:  Shusuke Numata; Makoto Kinoshita; Atsushi Tajima; Akira Nishi; Issei Imoto; Tetsuro Ohmori
Journal:  BMC Med Genet       Date:  2015-07-26       Impact factor: 2.103

5.  Multi-regression analysis revealed a relationship between l-serine and methionine, a component of one-carbon metabolism, in the normal control but not in the schizophrenia.

Authors:  Yumiko Takano; Yuji Ozeki; Masae Sekine; Kumiko Fujii; Takashi Watanabe; Hiroaki Okayasu; Takahiro Shinozaki; Akiko Aoki; Kazufumi Akiyama; Hiroshi Homma; Kazutaka Shimoda
Journal:  Ann Gen Psychiatry       Date:  2016-08-31       Impact factor: 3.455

6.  SAP97 regulates behavior and expression of schizophrenia risk enriched gene sets in mouse hippocampus.

Authors:  Preetika Gupta; Ogul E Uner; Soumyashant Nayak; Gregory R Grant; Robert G Kalb
Journal:  PLoS One       Date:  2018-07-11       Impact factor: 3.240

7.  Homocysteine-lowering gene therapy rescues signaling pathways in brain of mice with intermediate hyperhomocysteinemia.

Authors:  Vanessa Baloula; Marta Fructuoso; Nadim Kassis; Dalale Gueddouri; Jean-Louis Paul; Nathalie Janel
Journal:  Redox Biol       Date:  2018-08-25       Impact factor: 11.799

Review 8.  Improvement of Psychotic Symptoms and the Role of Tissue Plasminogen Activator.

Authors:  Silvia Hoirisch-Clapauch; Antonio E Nardi
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

Review 9.  Dysfunction in the coagulation system and schizophrenia.

Authors:  S Hoirisch-Clapauch; O B Amaral; M A U Mezzasalma; R Panizzutti; A E Nardi
Journal:  Transl Psychiatry       Date:  2016-01-05       Impact factor: 6.222

10.  Effect of Aerobic Exercise on Improving Symptoms of Individuals With Schizophrenia: A Single Blinded Randomized Control Study.

Authors:  Peng-Wei Wang; Huang-Chi Lin; Chwen-Yng Su; Ming-De Chen; Kuo C Lin; Chih-Hung Ko; Cheng-Fang Yen
Journal:  Front Psychiatry       Date:  2018-05-15       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.